interleukin-2


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.
Related to interleukin-2: Proleukin

interleukin-2

[‚in·tər¦lük·ən ′tü]
(immunology)
A lymphokine secreted mostly by helper T lymphocytes that promotes the growth of T lymphocytes. Abbreviated IL-2.
References in periodicals archive ?
Baseline serum anti-interleukin-2 autoantibody levels did not affect low-dose interleukin-2 therapeutic effects
In 2015, the Journal of the American Academy of Dermatology reported on another study that used interleukin-2 and other immune boosters.
Randomized Trial of Adjunctive Interleukin-2 in Adults With Pulmonary Tuberculosis.
In our research work we selected Interleukin-2, because it plays an important part in immune response to infectious diseases, in particular, where T-helper cell defense is required.
Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or =300/[mm.sup.3]: CPCRA 059.
There was a "major improvement in survival" among the patients with liver metastases who were treated with the combination, compared with those treated with interleukin-2 (IL-2) alone, reported one of the investigators, Dr.
Using this approach, Avigen and collaborators at the Nagoya University School of Medicine (Japan) have employed adeno-associated virus to transfer the thymidine kinase gene in combination with interleukin-2 to experimental gliomas in mice.
We gave several different levels of nine vitamins and minerals to 11 to 15 senior citizens for one year and then measured the changes in their levels of natural killer cells, T cells, and interleukin-2. We also looked at how often they got sick.
The Unituxin/RA arm consisted of Unituxin in combination with granulocyte macrophage-colony stimulating factor and RA, Unituxin in combination with interleukin-2 and RA and RA.
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
Daclizumab binds to the alpha chain of the interleukin-2 receptor on T cells, thereby blocking interleukin-2 activity that would lead to T-cell mobilization and proliferation.
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.